AbbVie (NYSE:ABBV) Trading 2.1% Higher – What’s Next?

21 May 2026, 21:34 by Renee Jackson · The Cerbat Gem

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price traded up 2.1% during trading on Tuesday . The stock traded as high as $215.80 and last traded at $213.7730. 7,152,122 shares traded hands during mid-day trading, an increase of 2% from the average session volume of 7,036,760 shares. The stock had previously closed at $209.41.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics unit, received a positive CHMP opinion in Europe for Boey® (trenibotulinumtoxinE) to treat moderate to severe glabellar lines, a step that could expand AbbVie’s aesthetics franchise if formal approval follows. Article: Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Positive Sentiment: AbbVie said it will present new oncology data at ASCO 2026, highlighting momentum across its next-generation cancer pipeline in solid tumors and blood cancers, which supports longer-term growth expectations. Article: AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Positive Sentiment: Piper Sandler reiterated an Overweight rating and raised its price target on AbbVie, citing strength in the company’s inflammatory bowel disease pipeline and Skyrizi-related progress. Article: AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength
Neutral Sentiment: Analyst-style articles on undervaluation may offer some support to investor sentiment, but they do not appear to be direct company-specific catalysts for ABBV. Article: 3 Stocks That May Be Undervalued By The Market In May 2026
Negative Sentiment: AbbVie also faces some headline risk after reports that its patent plea for the hepatitis C drug Mavyret was rejected in India, which could weigh on sentiment around parts of its older portfolio. Article: AbbVie’s Patent Plea for Hepatitis C Therapy Mavyret Rejected in India

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Piper Sandler boosted their price target on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

Check Out Our Latest Report on ABBV

AbbVie Price Performance

The business’s 50 day moving average is $208.95 and its 200 day moving average is $219.71. The stock has a market cap of $379.60 billion, a price-to-earnings ratio of 105.84, a P/E/G ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 earnings per share. As a group, analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current year.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Several large investors have recently bought and sold shares of the stock. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter valued at about $26,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at about $28,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at about $29,000. Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at about $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.